Abstract: The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.
Abstract: Disclosed are halogenated 2-deoxy-lactone, 2?-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.
Abstract: Compositions comprising C5 and C6 saccharides of varying degrees of polymerization and low levels of undesirable impurities, such as compounds containing sulfur, nitrogen, or metals, are disclosed.
Type:
Grant
Filed:
March 18, 2015
Date of Patent:
October 10, 2017
Assignee:
Renmatix, Inc.
Inventors:
Daniel Clay Floyd, Kiran Kadam, Srinivas Kilambi
Abstract: A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10 % by weight to 20 % by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose.
Abstract: The present invention concerns the antidiabetic-activity of compounds type A, namely of 8-?-D-glucosylgenistein, which is not toxic to eukaryotic cells and has demonstrated to produce complete normalization of fasting hyperglycaemia, to reduce excessive postprandial glucose excursion, to increase glucose-induced insulin secretion and insulin sensitivity. An alternative synthesis for this molecular entity and its binding ability to ?-amyloid oligomers is also included in the present invention, which also comprises Genista tenera ethyl acetate extract for use as antihyperglycaemic, agent i.e. for lowering blood glucose levels in mammals that are pre-diabetic or have type 2 or type 1 diabetes. The inhibitory activity of ?-glucosidase by Genista tenera ethyl acetate and butanol extracts and that of glucose-6-phosphatase by these two extracts and the diethyl ether plant extract is also part of the present invention.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
October 3, 2017
Assignee:
FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA
Inventors:
Amélia Pilar Grases Santos Silva Rauter, Ana Rita Xavier De Jesus, Alice Isabel Mendes Martins, Catarina Alexandra Dos Santos Dias, Rogério José Tavares Ribeiro, Maria Paula Borges De Lemos Macedo, Jorge Alberto Guerra Justino, Helder Dias Mota Filipe, Rui Manuel Amaro Pinto, Bruno Miguel Nogueira Sepodes, Margarida Alexandra Patrício Goulart De Medeiros, Jesus Jimenéz Barbero, Cristina Airoldi, Francesco Nicotra
Abstract: There is provided a process for the preparation of Lacosamide in a particular polymorphic form, which process involves the isolation of a salt of formula I: according to the methods defined in the application.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
September 26, 2017
Assignees:
Cambrex Karlskoga AB, Cambrex Profarmaco Milano
Inventors:
Stefano Radaelli, Giuseppe Zurlo, Lars Eklund, Margus Eek, Ants Maasalu, Malle Schmidt
Abstract: The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.
Abstract: Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.
Type:
Grant
Filed:
June 6, 2013
Date of Patent:
September 19, 2017
Assignee:
Galectin Therapeutics, Inc.
Inventors:
Peter G. Traber, Eliezer Zomer, Anatole A. Klyosov
Abstract: Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Type:
Grant
Filed:
December 22, 2011
Date of Patent:
September 19, 2017
Assignee:
ABBOTT LABORATORIES
Inventors:
Rachael Buck, Debra L. Thomas, Joseph P. Schaller
Abstract: Compounds which allosterically modulate and/or inhibit factor XIa activity are provided, as are methods of their use. These compounds include i) sulfated gallolyl glucosides, ii) sulfated quinazolinones, and iii) sulfated inositol analogs. The compounds used as anticoagulant agents.
Type:
Grant
Filed:
November 12, 2013
Date of Patent:
September 12, 2017
Assignee:
Virginia Commonwealth University
Inventors:
Umesh R. Desai, Rajesh Karuturi, Akul Mehta, Rami A. Al-Horani
Abstract: The invention relates to the field of carbohydrate chemistry. Provided is a process for the regioselective oxidation of a single secondary hydroxy function of a carbohydrate substrate comprising two or more secondary hydroxy functions, comprising contacting the carbohydrate substrate in a solvent in the presence of a transition metal catalyst complex with an oxidizing agent to yield a mono-oxidized carbohydrate.
Type:
Grant
Filed:
June 20, 2013
Date of Patent:
September 5, 2017
Assignee:
Rijksuniversiteit Groningen
Inventors:
Adriaan Jacobus Minnaard, Manuel Jäger, Aditya Lakshmi Narasimha Raju Gottumukkala, Johannes Gerardus de Vries, Andreas Alexander Bastian, Andreas Herrmann
Abstract: The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.
Abstract: The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular, the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (DP) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of Type-2 Diabetes Meliitus (T2DM). Said compositions are also used for preventing the development of, or ameliorating, side-effects or conditions in a subject treated with sulfonylurea and/or a sulfonamide compounds (and/or derivatives and/or metabolites thereof, or combinations thereof), said side-effects including hypoglycemia, gastrointestinal disturbances, fatigue, weight gain, and satiety.
Abstract: The present invention relates to glycogen-based cationic polymers, to complexes of the said cationic polymers with anionic compounds, to pharmaceutical compositions comprising the said complexes, and to the use of the said complexes for delivering or transfecting the said anionic compounds to a specific pharmacological target, such as, for instance an organ, a tissue or a cell.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
August 1, 2017
Assignee:
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
Abstract: An agent for treating heart failure, which improves left ventricular diastolic function itself without depending on the diuretic effect or vasodilation effect; controls the pathological condition of diastolic functional failure; and prevents the recurrence, and can prevent dyspnea and death from the pathological condition, is provided. By directly acting on a heart, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid improves left ventricular diastolic function, and can effectively treat diastolic functional failure among heart failure types. Accordingly, by present invention, a new agent for treating heart failure that can relieve diastolic functional failure, for which no effective therapeutic method has been established, can be provided.
Abstract: The present invention relates to novel fungicidal compound including an aminoglycoside analog having certain substituents at the 6 position of ring III that exhibit improved antifungal activity but possess minimal antibacterial properties in combination with fungicidal azoles. The aminoglycoside compounds are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
June 6, 2017
Assignee:
Utah State University
Inventors:
Jon Y. Takemoto, Cheng-wei Tom Chang, Sanjib K. Shrestha, Michelle Grilley
Abstract: The present invention relates to a novel pharmaceutical composition for serotonin reuptake inhibition, wherein the composition comprises pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients. Also the present invention relates to a process of preparation of novel pharmaceutical composition for serotonin reuptake inhibition, wherein the process comprising steps of: (a) obtaining extract from the plant Centella asiatica; (b) treating the extract with the solvents to remove fatty substances, chlorophyll and other colorants; (c) purifying the extract through HPLC to obtain the eluted solvent; and (d) concentrating the eluted solvent to arrive at the composition. The invention also relates to the use of a composition comprising pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients to manufacture a medicament for serotonin reuptake inhibition in a subject in need thereof.
Abstract: Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2?-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.
Abstract: The present invention relates to compositions comprising: (a) at least two phenolic compounds (one flavoid and one non-flavoid); (b) at least one hydrotrope; (c) at least one emulsifier; (d) a lipid-soluble antioxidant; and (e) water. The at least one hydrotrope should be present in an amount that is effective to solubilize said at least two phenolic compounds in the water phase of the composition. The at least one emulsifier should be present in an amount sufficient to create a water-in-oil or oil-in-water emulsion that is effective to solubilize the lipid-soluble antioxidant. The compositions are useful for cosmetic purposes and other uses.
Type:
Grant
Filed:
July 1, 2013
Date of Patent:
June 6, 2017
Assignee:
L'OREAL
Inventors:
Nannan Chen, Patricia Brieva, Donna McCann, Anthony Potin
Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.